BioWorld

April 10, 2006

'Extensive' Bidding War Ends With Pfizer Taking Over Rinat

After an almost year-long respite, Pfizer Inc. is throwing money on the biotech table again, this time entering an agreement to buy privately held Rinat Neuroscience Corp. for an undisclosed sum. (BioWorld Today) Read More

Midwest's Chance To Shine: BIO 2006 Arrives In Chicago

Four Points Of Concern As Biotechnology Grows

Cougar Goes Public Through Reverse Merger, Raises $47M

Biotech Execs Ask For BioShield Reform; Security, Money At Issue

Medarex's Public Offering Gets $112M For R&D, Clinical Work

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Feb. 5, 2025.

MicroRNAs in circulating extracellular vesicles as IPF biomarkers

BioWorld Science

MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...

MJFF grant supports Bexorg’s translational biomarker work

BioWorld Science

Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...

REST emerges as biomarker in ALS, knockdown improves ALS symptoms

BioWorld Science

About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...

Illustration of liver being targets with cross-hairs

Study identifies CAND1 as therapeutic target in hepatoblastoma

BioWorld Science

Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...